Neoadjuvant chemotherapy (NAC) is used in patients with breast cancer to reduce tumor focus, metastatic risk, and patient mortality. Monitoring NAC effects is necessary to capture resistant patients and stop or change treatment. The existing methods for evaluating NAC results have some limitations. The aim of this study was to assess the tumor response at an early stage, after the first doses of the NAC, based on the variability of the backscattered ultrasound energy, and backscatter statistics. The backscatter statistics has not previously been used to monitor NAC effects.
Abstract
Neoadjuvant chemotherapy (NAC) is used in patients with breast cancer to reduce tumor focus, metastatic risk, and patient mortality. Monitoring NAC effects is necessary to capture resistant patients and stop or change treatment. The existing methods for evaluating NAC results have some limitations. The aim of this study was to assess the tumor response at an early stage, after the first doses of the NAC, based on the variability of the backscattered ultrasound energy, and backscatter statistics. The backscatter statistics has not previously been used to monitor NAC effects.
The B-mode ultrasound images and raw radio frequency data from breast tumors were obtained using an ultrasound scanner before chemotherapy and 1 week after each NAC cycle.
Twenty-four malignant breast cancers, qualified for neoadjuvant treatment before surgery, were included in the study. The shape parameter of the homodyned K distribution and integrated backscatter, along with the tumor size in the longest dimension, were determined based on ultrasound data and used as markers for NAC response. Cancer tumors were assigned to responding and non-responding groups, according to histopathological evaluation, which was a reference in assessing the utility of markers. Statistical analysis was performed to rate the ability of markers to predict the final NAC response based on data obtained after subsequent therapeutic doses. Statistically significant differences between groups were obtained after 2, 3, 4, and 5 doses of NAC for quantitative ultrasound markers and after 5 doses for the assessment based on maximum tumor dimension. After the second and third NAC courses the marker, which was a linear combination of both quantitative ultrasound parameters, was characterized by an AUC of 0.82 and 0.91, respectively.
The introduction of statistical parameters of ultrasonic backscatter to monitor the effects of chemotherapy can increase the effectiveness of monitoring and contribute to a better personalization of NAC therapy.
Introduction
Neoadjuvant chemotherapy (NAC) was initially used in locally advanced breast cancer (LABC) and in the case of inflammatory cancer [1] . Currently, it is also recommended in patients with triple-negative cancer (TNBC), with the presence of HER-2 + receptors (Luminal B HER2-positive and HER-positive non-luminal subtype), and in cases of luminal B HER2-negative tumors with low expression of hormone receptors, with high grade of malignancy (G3) in patients at an early age (≤ 35 years) in the second or third stage of cancer [2] [3] [4] . Neoadjuvant chemotherapy reduces the risk of metastases and micrometastases in distant organs. It also reduces the neoplastic focus and decreases the frequency of the recurrences and the mortality of patients.
The use of NAC therapy does not always bring the expected results. A meta-analysis conducted on a group of over 18,000 patients (from 49 studies) who received NAC showed that the pathologic complete response rate was 21.5% [5] . In the HER2-positive disease and the triple-negative disease groups, the percentages of complete responses for the treatment reached 76 and 67%, respectively [5] . The complete response is significantly lower in the case of the luminal B HER2-negative subtype, but patients with additional risk factors may also benefit from pre-operative treatment. According to available data, even over 40% of patients undergoing chemotherapy show a poor pathological response to the treatment [6] . In such cases, the whole cycle of neoadjuvant therapy, which lasts about 4 months (five cycles), is associated with the delayed start of another, more effective treatment and unnecessary exposure of the patient to the toxic effects of the drugs used. The response to the treatment varies and requires differentiation between responders and non-responders.
For monitoring, a clinical breast examination (CBE), mammography (MMG), traditional ultrasound imaging in B-mode (US), and magnetic resonance imaging (MRI) are used. Imaging with MRI is more accurate compared to CBE, US, or MMG; however, MRI is a technique with limited availability. Ultrasonography is considered a more accurate method in assessing tumor size and in the monitoring of residual breast tumors than CBE or MMG [7] . Recent work has also shown that classical US imaging techniques with sonoelastography are useful and allow predicting the response to the treatment with a high degree of sensitivity and specificity after the second course of chemotherapy. The decrease in tumor stiffness is a good predictor of a pathological response [8] .
Methods based on monitoring changes in tumor size, which are determined on the basis of imaging tests or by palpation examination, have numerous limitations [7] . Changes in tumor size occur with a delay in relation to changes in the tumor microstructure. Sometimes, despite a positive pathological response to the treatment, there is no apparent reduction in primary tumor mass in imaging because it is masked by changes induced by the treatment.
Functional imaging techniques, such as positron emission tomography, MRI with contrast agents, diffusion weighted imaging, and diffuse optical spectroscopy, enable to capture changes in the microstructure, vascularization, and metabolic activity of tumors under the influence of chemotherapy after the first cycle of treatment [9] [10] [11] . However, these are costintensive and time-consuming methods which require intravenous administration of exogenous contrast agents to detect changes in the tumor after each course of chemotherapy.
Therefore, their use is limited.
The use of quantitative ultrasound (QUS) methods to assess the effectiveness of chemotherapy seems to be an interesting alternative to tracking changes in tumor size. The QUS techniques are based on the analysis of raw, ultrasonic radio-frequency echoes (RF) in order to determine the quantitative parameters characterizing the tissue. The QUS technique was also used to monitor the breast cancer response to chemotherapy. For example, Lin et al.
used animal models of breast cancer to show that the spectral analysis of ultrasonic echoes provides a way to assess the tumor response to chemotherapy [12] . Similarly, Sannachi et al.
carried out a study on a group of 30 tumors and showed that the use of a combination of quantitative measures: average scatterer diameter (ASD), and average acoustic concentration (AAC) allows for the differentiation of responding and non-responding patients, with a sensitivity of 82% and a specificity of 100% after the fourth week of treatment [13] . In later studies, Sannachi et al., based on a combination of quantitative parameters: texture, and molecular features, predicted tumor response to NAC with an accuracy of 79, 86, and 83% at weeks 1, 4, and 8 of the therapy, respectively [14] . Sadeghi-Naini et al. presented clinical trials using QUS on a group of 100 patients [15] 
Materials and methods

Patients
The study was carried out in the Department of Radiology, Maria Skłodowska-Curie Memorial Institute of Oncology in Warsaw, Poland.
The study included patients with breast cancer qualified for neoadjuvant chemotherapy (NAC) prior to mastectomy. The group consisted of patients with operable (T2-3, N0-2, M0) or locally advanced (T4a-d, N0-2, M0) tumors.
The Institutional Review Board approved the study protocol. All procedures performed in the study that involved human participants were in accordance with the guidelines set by the 1964 WMA Declaration of Helsinki and its later amendments or comparable ethical standards. All patients signed the informed consent for breast US examination and for ‛backscatter US' statistical studies.
The US examinations were performed in 16 patients aged 32 to 83 years (median 53.5). Three patients had bifocal lesions and two patients had three-focal lesions, resulting in a total of 24 tumors for examination. Data from each cancer were processed separately. One tumor was non-specific type (NST) with ductal carcinoma in situ (DCIC), while the remaining tumors were NST. Lesions were verified as invasive carcinoma NST G2 (15), G3 (6) , and G1 (3). There were five luminal A cancers, five luminal B Her2+, 10 luminal B Her 2-, two TNBC, and two HER2+. The NAC treatments were administered according to the international guidelines in the protocol: AC (doxorubicin, cyclophosphamide), taxol and trastuzumab were used. In one patient with a history of breast cancer, AT (doxorubicin, docetaxel) was used. All patients underwent a simple mastectomy with lymphadenectomy.
Ultrasound data acquisition
The B-mode ultrasound (US) images and raw Radio Frequency data (RF) from the breast tumors were acquired using an ultrasonic scanner (Ultrasonix Sonix Touch-Research, Ultrasonix Medical Corporation, Richmond, BC, Canada) with a linear array transducer L14-5/38 and a transmit frequency of 7 MHz (-6 dB bandwidth range of 4-9 MHz). The focus was set to the lower part of the tumors. Data samples were recorded with a sampling frequency of 40 MHz and a 16-bit precision. Each data frame consisted of 510 lines, which corresponded to ~40 mm. The measurement scheme included ultrasound data registration in four tumor planes (radial, radial + 45°, anti-radial, anti-radial +45°). The ultrasound examinations were performed in accordance with the American College of Radiology BI-RADS guidelines [16] .
The region of interest (ROI) contoured around the tumor was determined by the same, experienced radiologist during each scan. The size of the tumor in the longest dimension was also measured.
The first scan was acquired before chemotherapy and was used as the baseline data.
Subsequent ultrasound examinations were performed 1 week after each course of NAC; the patient was monitored for 5 to 6 months. All patients underwent the first four cycles of NAC, but some patients did not take part in subsequent stages of chemotherapy due to the oncologist's decision to perform a mastectomy or in the event of complete disappearance of the tumor.
Quantitative ultrasound parameters
Two QUS parameters were used, the integrated backscattering coefficient (IBSC) and the shape parameter of the homodyned K distribution. The hypothesis underlying their use is that changes in the structure and function of the tumor associated with the effects of chemotherapy result in changes in the basic physical properties of the tissue. These properties can be quantified with indicators dependent on the frequency and the backscatter statistics.
The IBSC quantifies the energy of backscattering and depends on the size and physical properties of the scatterers, their concentration, and the randomness of parameters. The shape parameter of the homodyned K distribution depends on the effective number of scattering (ENS) elements in the resolution cell.
The distribution of IBSC and ENS values in the tumor was presented in the form of parametric maps, which were generated using the sliding window technique. The window was moving pixel by pixel, in the horizontal and vertical directions, in the area of the ROI covering the entire tumor area. The parameters IBSC and ENS were calculated based on ultrasound RF data from each window. The window had dimensions of 3 mm by 3 mm, which meets the window size requirements for obtaining reliable scatterer property estimates [17, 18] . The tumor response to the treatment was analyzed by assessing the mean IBSC values and the mean ENS values obtained in all windows of the four parametric maps corresponding to the four tumor sections.
The RF signal analysis and the estimation of the quantitative ultrasonic parameters were performed off-line using in-house software written in the Matlab environment (Mathworks, Natick, MA, USA).
Integrated backscatter coefficient
The integrated backscatter coefficient was derived from estimates of the backscatter coefficient (BSC), which is defined as the differential scattering cross section per unit solid angle at 180° per unit volume. The BSC was determined using the reference phantom method proposed by Yao et al. [19] . The technique allows limiting the impacts of system-dependent effects such as the system transfer function or diffraction artifacts by using data from the well- 
Envelope statistics
The envelope statistics was based on the homodyned K distribution, which was first introduced by Jakeman [23] ; this model of backscatter was chosen because of its flexibility.
The high usability of homodyned K distribution stems from the ability to describe statistics of envelopes of signals under varying conditions. This means that homodyned K distribution may be used when the number of scatterers is large and when they are uniformly distributed as well as when the number of scatterers is low or they are organized in periodical structures or in case of coherent component sources. Additionally, the shape parameter of the homodyned K distribution has shown that it may be used as an ultrasonic biomarker which characterizes the tissue microstructure [24] . The shape parameter ENS, also called "effective number of scatterers", is defined as ENS , where is the real number of scatterers and describes the level of clustering. The method proposed by Hruska and Oelze was used to determine ENS [25] .
Statistical analysis Additionally, a tumor size-based classifier was included in the analysis.
The statistical significance of the classifiers was assessed using p-values obtained with a twosided Wilcoxon rank sum test. The classifiers were cross-validated through the leave-one-out technique [27] . Evaluation of the results was based on the area under the receiver operating characteristic (ROC) curve (AUC) [28] ; these values were determined for data acquired after each chemotherapy course. The results were analyzed for changes in classification effectiveness as a function of the therapy progress. All calculations were done using Matlab® 2018a (The MathWorks, Inc., Natick, MA).
Results and discussion
Pathologic responses to treatment
Tumor tissue specimens were histologically evaluated for assessment of the effects of Microscopic analysis of the samples shows the changes occurring as a result of the NAC, which is important for the scattering of ultrasounds. In the case of the PR tumors, we observed a decrease in cellularity, formation of fibrosis, and stromal edema. Microscopic images of cancer samples for responding and non-responding tumors are shown in Fig 1. The RMC values for these tumors after NAC treatment were 0 and 100%, respectively.
Microscopic evaluation of the specimens revealed the presence of stroma-filled tissue (pink staining) with small isolated patches of glands (purple staining), demonstrating therapeutic effects (Fig 1a) . In Fig 1b, high cellularity with low stromal collagen density is visible.
Assessment of the usefulness of QUS parameters and of the tumor size to predict the effects of chemotherapy was based on a comparison with RMC results. 
QUS parametric maps
Cycles of representative B-mode ultrasound images for responding (0% RMC) and nonresponding (100% RMC) tumors are shown in Figure 3 , together with the parametric overlays of the IBSC and ENS maps. They were calculated based on ultrasound data collected immediately before NAC treatment and 1 week after each NAC course. The pixel color reflects the parameter value and the position depends on the location of the sliding window.
Analysis of the IBSC map set revealed a clear upward trend in the IBSC values of responding tumors (Fig 3, first column) . In the case of non-responding tumors, no such changes were observed (second column). For the responding tumor, the ENS values decreased as the treatment progressed (Fig 3, third column) . In the case of a non-responding tumor, there was no clear trend in ENS changes (last column). NAC suggests that other scattering structures are the main sources of scattering after chemistry doses. Changes occurring in cancer tissue during chemotherapy concern both changes at the cell level and changes in the stroma tissue structure. The nuclear structure of the cell and its physical parameters such as density, elasticity, and viscosity, are changing [33] , and the condensation of the cell's nucleus during apoptosis increases the ultrasound scattering [34] . On the other hand, the stromal microenvironment undergoes changes in the blood vessel architecture and the extracellular matrix composition [35, 36] . In the stroma, fibrosis, collagenization, and microcalcification are associated with structures strongly scattering ultrasounds. It can be assumed that before therapy, ultrasound scattering on tumor cell clusters plays a significant role in the scattered signal. In the case of effective chemotherapy, the newly formed structures of the repair processes, such as excess fibrous connective tissues, significantly contribute to the scattering of the ultrasound; based on their size and mechanical properties, they are scatterrers influencing the value of the ENS parameter.
In one case, in the group of tumors that did not respond, a reduced ENS value after NAC treatment was found. It was an invasive NST breast cancer with in situ ductal carcinoma (DCIS), while the remaining tumors were NST type. In DCIS tumors, cancer cell proliferation occurs inside the ducts and does not infiltrate the surrounding tissue. Thus, it can be assumed that in this case a small decrease in the EDS parameter was due to the fact that changes in tumor cells during NAC occurred in the ducts, while the surrounding tissues and stroma did not show similar changes as in infiltrated cancer.
The increase in IBSC value was the reaction of cancerous tissue to NAC in the case of a positive histopathological result. In the group of non-responders, IBSC decreased or remained unchanged. After completion of the NAC treatment, only in one case of the nonresponding tumors, a small increase in the IBSC value was found, and in one case of responding tumors, this value decreased. This behavior of IBSC confirms the results of another study which showed an increase in the backscattering coefficient of ultrasound in the breast tumor, in the 4-9 MHz range, as a positive response to chemotherapy [13] .
The QUS parameters are also shown in the IBSC-ENS plane (Fig 5) , 
Classification and statistical analysis results
Statistical analysis was performed to distinguish between response cases and no response based on ENS, IBSC, IBSC + ENS, or tumor size, features used as biomarkers for NAC response. The statistical significance of the differences between the NAC-responsive groups and the groups that did not respond was evaluated with the p-values shown in Table 1 , where statistically significant differences (p < 0.05) are marked in gray. The progressive separation of responding and non-responding groups ( Table 2 . Fig 6a) . A combination of QUS parameters allowed improving the AUC after the second, the third, and the fourth NAC course (Fig. 6b ).
The main difference in the efficiencies of classification based on the IBSC + ENS composite classifier and the classification based on the size of tumors is the different stage of NAC in obtaining a similar AUC (Fig 6b) . This difference, however, is extremely important because the early diagnosis of N-PR tumors is fundamental to personalize the treatment and allows oncologists to make an early decision depending on the effectiveness of the NAC.
For an assessment based on tumor size, often used in clinical evaluation, effective classification is only possible after NAC stage 4 and 5 (AUC = 0.75 and 0.90 respectively).
For a combined QUS classifier a comparable AUC is available after the second and third NAC courses respectively. This delay in tumor size reduction results from the lower rate of the tissue repair process, manifested by the disappearance of the tumor, compared to the changes taking place in the cells and tissue structure.
Conclusions
The results obtained suggest that ENS provides useful information to monitor NAC. Supporting information S1 
